Office Management of Female Pelvic Floor Dysfunction

Chapter

Abstract

As the population of the United States ages, more women will present to their primary care provider or gynecologist with symptoms of pelvic floor dysfunction. Pelvic floor dysfunction includes urinary incontinence, voiding difficulties, and pelvic organ prolapse. A thorough history and physical exam is important to rule out any pelvic pathology, such as bladder cancer, which could present with overactive bladder symptoms. While a patient who wishes to proceed with surgical management for these issues may need referral to a specialist, many of these patients can undergo conservative management initially with office-based therapies. Pessaries are effective for managing prolapse and in certain cases of stress incontinence. Behavioral and medical management can improve urge incontinence and voiding dysfunction. The general gynecologist should be familiar with the basic evaluation of pelvic floor disorders, office-based treatments, and the appropriate terminology for these disorders to assist with communication when referral is indicated.

Keywords

Prolapse Incontinence Pessary Voiding dysfunction Office management 

References

  1. 1.
    Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, et al. Prevalence of symptomatic pelvic floor disorders in US women. JAMA. 2008;300:1311–6.CrossRefGoogle Scholar
  2. 2.
    Wu JM, Matthews CA, Conover MM, Pate V, Funk MJ. Lifetime risk of stress incontinence or pelvic organ prolapse surgery. Obstet Gynecol. 2014;123:1201–6.CrossRefGoogle Scholar
  3. 3.
    Wu JM, Hundley AF, Fulton RG, Myers ER. Forecasting the prevalence of pelvic floor disorders in U.S women: 2010 to 2050. Obstet Gynecol. 2009;114:1278–83.CrossRefGoogle Scholar
  4. 4.
    United States Census Bureau [homepage on the Internet]. 2012 National population projections: summary tables. Table 2. Projections of the population by selected age groups and sex for the United States: 2015 to 2060. Available from : http://www.census.gov/population/projections/data/national/2012/summarytables.html. Accessed 27 Mar 2013.
  5. 5.
    Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN, International Urogynecological Association, International Continence Society. An international Urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20.PubMedGoogle Scholar
  6. 6.
    Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.PubMedGoogle Scholar
  7. 7.
    Swift S, Morris S, McKinnie V, Freeman R, Petri E, Scotti RJ, et al. Validation of a simplified technique for using the POPQ pelvic organ prolapse classification system. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(6):615–20.CrossRefGoogle Scholar
  8. 8.
    Mandel FP, Geola FL, Meldrum DR, Lu JH, Eggena P, Sambhi MP, et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab. 1983;57(1):133–9.CrossRefGoogle Scholar
  9. 9.
    O’Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 2001;93(10):754–62.CrossRefGoogle Scholar
  10. 10.
    Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol. 1994;84:215.PubMedGoogle Scholar
  11. 11.
    Hanson LA, Schulz JA, Flood CG, Cooley B, Tam F. Vaginal pessaries in managing women with pelvic organ prolapse and urinary incontinence: patient characteristics and factors contributing to success. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17:155–9.CrossRefGoogle Scholar
  12. 12.
    Kegel AH. Progressive resistance exercise in the functional restoration of the perineal muscles. Am J Obstet Gynecol. 1948;56:238–48.CrossRefGoogle Scholar
  13. 13.
    Moen MD, Noone MB, Vassallo BJ, Lopata R, Nash M, Sum B. Knowledge and performance of pelvic muscles exercises in women. J Pelvic Med Surg. 2007;13:113–7.CrossRefGoogle Scholar
  14. 14.
    Moen MD, Noone MB, Vassallo BJ, Elser DM. Pelvic floor muscle function in women presenting with pelvic floor disorders. Int Urogynecol J. 2009;20:843–6.CrossRefGoogle Scholar
  15. 15.
    Wu V, Farrell SA, Baskett TF, Flowerdew G. A simplified protocol for pessary management. Obstet Gynecol. 1997;90:990–4.CrossRefGoogle Scholar
  16. 16.
    Culligan PJ. Nonsurgical management of pelvic organ prolapse. Obstet Gynecol. 2012;119:852–60.CrossRefGoogle Scholar
  17. 17.
    Richter HE, Burgio KL, Brubaker L, Nygaard IE, Ye W, Weidner A, Bradley C, Handa VL, Borello-France D, Goode PS, Zyczynski H, Lukacz ES, Schaffer J, Barber M, Meikle S, Spino C. For the pelvic floor disorders network. A trial of continence pessary vs. behavioral therapy vs. combined therapy for stress incontinence. Obstet Gynecol. 2010;115:609–17.CrossRefGoogle Scholar
  18. 18.
    Robert M, Ross S. Conservative management of urinary incontinence. J Obstet Gynaecol Can. 2006;28:1113–8.CrossRefGoogle Scholar
  19. 19.
    Lewis CM, Salamon C, Culligan P. Uncomplicated vaginal delivery following midurethral sling. Female Pelvic Med Reconstr Surg. 2011;17:147–8.CrossRefGoogle Scholar
  20. 20.
    Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A, Tolteridine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57:414–21.CrossRefGoogle Scholar
  21. 21.
    Dmochowski RR, Sand PK, Zinner NR, Transdermal Oxybutynin Study Group, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237–42.CrossRefGoogle Scholar
  22. 22.
    Foote J, Glavind K, Kralidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol. 2005;48:471–7.CrossRefGoogle Scholar
  23. 23.
    Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety, and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007;178:2488–94.CrossRefGoogle Scholar
  24. 24.
    Appel RA, Sand P, Dmochowski R, Overactive Bladder: Judging Effective Control and Treatment Study Group, et al. Prospective randomized control trial of extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78:687–95.CrossRefGoogle Scholar
  25. 25.
    Gehrich A, Stany MP, Fischer JR, Buller J, Zahn CM. Establishing a mean postvoid residual volume in asymptomatic perimenopausal and postmenopausal women. Obstet Gynecol. 2007;110:827–32.CrossRefGoogle Scholar
  26. 26.
    Laycock J. Clinical evaluation of the pelvic floor. In: Schussler B, Laycock J, Norton P, Stanton SL, editors. Pelvic floor re-education. London: Springer-Verlag; 1994. p. 42–8.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyHackensack University Medical CenterHackensackUSA
  2. 2.Department of Obstetrics and GynecologyRosalind Franklin University Chicago Medical School, Advocate Lutheran General HospitalPark RidgeUSA

Personalised recommendations